$142 Million is the total value of Aquilo Capital Management, LLC's 11 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 30.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | SPDR SERIES TRUSTput | $38,125,000 | -13.1% | 500,000 | 0.0% | 26.85% | +76.4% | |
| MRUS | Sell | MERUS N V | $18,510,000 | -9.2% | 1,038,746 | -25.4% | 13.04% | +84.2% |
| QURE | New | UNIQURE NVcall | $15,744,000 | – | 400,000 | +100.0% | 11.09% | – |
| QURE | Buy | UNIQURE NV | $15,398,000 | -46.0% | 391,199 | +7.3% | 10.84% | +9.6% |
| SPRO | SPERO THERAPEUTICS INC | $12,236,000 | -7.9% | 1,154,356 | 0.0% | 8.62% | +86.8% | |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $10,088,000 | +47.8% | 2,958,243 | +103.8% | 7.10% | +199.9% |
| BCYC | Buy | BICYCLE THERAPEUTICS PLCsponsored ads | $8,736,000 | +17.7% | 767,026 | +4.0% | 6.15% | +138.8% |
| GLPG | Buy | GALAPAGOS NVspon adr | $8,677,000 | +43.7% | 56,840 | +21.3% | 6.11% | +191.6% |
| XENE | XENON PHARMACEUTICALS INC | $8,573,000 | -8.6% | 951,527 | 0.0% | 6.04% | +85.4% | |
| PRQR | Buy | PROQR THRAPEUTICS N V | $4,790,000 | -29.7% | 831,661 | +11.1% | 3.37% | +42.6% |
| FATE | Sell | FATE THERAPEUTICS INC | $1,122,000 | -90.8% | 72,273 | -88.0% | 0.79% | -81.4% |
| SYBX | Exit | SYNLOGIC INC | $0 | – | -1,043,922 | -100.0% | -3.30% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS IN | $0 | – | -557,455 | -100.0% | -5.13% | – |
| IBB | Exit | ISHARES TRput | $0 | – | -1,000,000 | -100.0% | -37.87% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.